Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001073496 | SCV001239039 | pathogenic | Retinal dystrophy | 2019-04-05 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001382259 | SCV001580939 | pathogenic | not provided | 2023-09-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Lys3128Argfs*7) in the EYS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 17 amino acid(s) of the EYS protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with retinitis pigmentosa (PMID: 29550188, 30153090). ClinVar contains an entry for this variant (Variation ID: 865915). This variant disrupts a region of the EYS protein in which other variant(s) (p.Tyr3135*) have been determined to be pathogenic (PMID: 18976725, 30337596). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. |
Gene |
RCV001382259 | SCV004034449 | likely pathogenic | not provided | 2023-03-06 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein extension, as the last 17 amino acids are replaced with 22 different amino acids; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30153090, 29550188, 33090715, 32728228) |
Baylor Genetics | RCV001833682 | SCV004192911 | pathogenic | Retinitis pigmentosa 25 | 2023-12-14 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001833682 | SCV002083447 | pathogenic | Retinitis pigmentosa 25 | 2021-03-01 | no assertion criteria provided | clinical testing |